Generation and characterisation of recombinant FMDV antibodies: Applications for advancing diagnostic and laboratory assays

Gareth Shimmon1*, Abhay Kotecha2, Jingshan Ren2, Amin S. Asfor1, Joseph Newman1, Stephen Berryman1, Eleanor M. Cottam1, Sarah Gold1, Toby J. Tuthill1, Donald P. King1, Emiliana Brocchi3, Andrew M. Q. King1, Ray Owens2, Elizabeth E. Fry2*, David I. Stuart2,4, Alison Burman1, Terry Jackson1

1 The Pirbright Institute, Pirbright, Surrey, United Kingdom, 2 Division of Structural Biology, University of Oxford, Headington, Oxford, United Kingdom, 3 Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna, Brescia, Italy, 4 Diamond Light Source, Harwell Science and Innovation Campus, Didcot, United Kingdom

* Current address: General Bioinformatics, Reading Enterprise Centre, Early, Reading, United Kingdom

* gareth.shimmon@pirbright.ac.uk (GS); liz@strubi.ox.ac.uk (EEF)

Abstract

Foot-and-mouth disease (FMD) affects economically important livestock and is one of the most contagious viral diseases. The most commonly used FMD diagnostic assay is a sandwich ELISA. However, the main disadvantage of this ELISA is that it requires anti-FMD virus (FMDV) serotype-specific antibodies raised in small animals. This problem can be, in part, overcome by using anti-FMDV monoclonal antibodies (MAbs) as detecting reagents. However, the long-term use of MAbs may be problematic and they may need to be replaced. Here we have constructed chimeric antibodies (mouse/rabbit D9) and Fabs (fragment antigen-binding) (mouse/cattle D9) using the Fv (fragment variable) regions of a mouse MAb, D9 (MAb D9), which recognises type O FMDV. The mouse/rabbit D9 chimeric antibody retained the FMDV serotype-specificity of MAb D9 and performed well in a FMDV detection ELISA as well as in routine laboratory assays. Cryo-electron microscopy analysis confirmed engagement with antigenic site 1 and peptide competition studies identified the aspartic acid at residue VP1 147 as a novel component of the D9 epitope. This chimeric expression approach is a simple but effective way to preserve valuable FMDV antibodies, and has the potential for unlimited generation of antibodies and antibody fragments in recombinant systems with the concomitant positive impacts on the 3Rs (Replacement, Reduction and Refinement) principles.

Introduction

Foot-and-mouth disease (FMD) is one of the most prevalent epizootic animal diseases affecting economically important livestock (e.g. cattle, buffalo, sheep, goats and pigs) and numerous
species of wild animal [1, 2]. FMD is greatly feared due to the enormous economic losses resulting from reduced productivity and trade restrictions on affected countries, and is recognised as a significant threat to global food security [2]. The causative agent, FMD virus (FMDV) is the type species of the Aphthovirus genus of the Picornaviridae. The virion comprises a molecule of single-stranded positive-sense RNA within a capsid composed of 60 copies each of four structural proteins, VP1, VP2, VP3 and VP4 [3–5]. The capsid proteins of FMDV are smaller than the corresponding proteins of most other picornaviruses, which render the FMDV capsid both thinner and smoother [3, 6]. A major exception is the so-called GH loop of VP1, which extends from the virion surface and forms an important antigenic site and also contains a highly conserved arginine-glycine-aspartic acid (RGD) motif that mediates attachment and cell entry by binding to integrin receptors [7–10].

FMDV exists as seven serotypes (O, A, C, Asia-1 and Southern African Territories [SAT] SAT-1, SAT-2 and SAT-3) with each serotype containing multiple and constantly evolving strains [11, 12]. A lack of immunological cross-reactivity between serotypes, and between some strains within a serotype greatly complicates FMD diagnosis and efforts to control FMD by vaccination [13]. Rapid, sensitive and serotype-specific assays are essential for FMD diagnosis, to restrict the spread of infection and to control and eradicate an outbreak. The gold standard, and the primary method currently used for diagnosis of FMD is a sandwich ELISA [14]. The ELISA can be carried out on clinical samples and is also used for virus serotyping [15]. The assay is reliable, easy and cheap to perform, and readily transferable to standard FMD laboratories. Other methods have been developed for detection and characterisation of FMDV, including field-based detection of capsids and genomes [16–19]. Nevertheless, it is likely that antibody based ELISA will remain important for both FMD diagnosis and serotype differentiation for the foreseeable future. However, the main disadvantage of the ELISA is that it requires anti-FMDV antibodies to all seven serotypes to both capture and detect the virus. Thus the assay necessitates the periodic need to generate high-affinity, sensitive, serotype-specific and consistent reagents, which can prove problematic. To overcome these problems a sandwich ELISA was recently developed that used recombinant integrin αvβ6 (the main receptor used by FMDV for cell entry [10]) in place of the rabbit polyclonal sera as the capture ligand, and serotype-specific monoclonal antibodies (MAbs) in place of the guinea pig polyclonal sera as the detecting reagents [20, 21]. The integrin/MAb ELISA was shown to detect FMDV strains of wide antigenic and molecular diversity, across all serotypes, and showed greater specificity compared to the conventional polyclonal antibody-based ELISA while retaining test sensitivity [20, 21]. Rapid chromatographic strip tests or lateral flow devices that also utilise MAbs are under development for so-called pen-side diagnosis of FMD [22–24]. Initially the above tests were based on a MAb that was pan-reactive against all FMDV serotypes [22, 24]. However, the long-term use of MAbs may also be problematic as hybridomas suffer from stability issues, which can result in reduced, or loss of antibody expression upon storage and/or prolonged cultivation [25–27]. Indeed, problems with the maintenance and storage of the hybridoma for the above pan-reactive FMDV antibody resulted in the loss of this MAb and an alternative MAb (and hybridoma) is now required for taking this forward [28].

A number of MAbs have been produced for various FMDV serotypes, which neutralise infectivity but also have the potential to be used for diagnosis of FMD. Some of these antibodies have been used to map the antigenic sites on the capsid through the generation of MAb-resistant mutants [29–39]. For the type O viruses, five neutralising antigenic sites were originally identified. Of these, antigenic site 1 has been of interest as it is located on the GH loop of VP1 and overlaps with the integrin-binding RGD tri-peptide. This loop is inherently flexible and adopts two main conformations (‘up’ or ‘down’); in the up conformation it forms essentially a series of overlapping linear epitopes, while in the down conformation, it forms a single
conformational epitope (antigenic site 5) which is formed by interactions with residues that lie under the loop footprint [32, 40, 41]. The other mapped antigenic sites (2, 3 and 4) are conformational and involve numerous residues of VP2 and VP3 [33–35, 39]. In addition, the existence of a sixth neutralising antigenic site has recently been proposed that involves residue 191 of VP2 [42]. For type O FMDV, one of the MAbs used to identify antigenic site 1 is known as D9 (MAb D9). This MAb was raised against the O, Switzerland 1965 strain [43] and used to generate escape mutants of a related virus, O1 Kaufbeuren (O1K) 1967. This study showed that MAb D9 can bind intact virions, isolated VP1 and a synthetic peptide (residues 141–160 of VP1) corresponding to the VP1 GH loop [39], but not trypsin treated virus, which cleaves the VP1 GH loop. At least three VP1 residues were implicated as being part of the D9 epitope, leucine (L)-144, L-148 and lysine (K)-154 but only the substitution at L-148, resulted in complete resistance to neutralisation [33, 39].

The modular structure of antibodies and the ability to generate small antigen-specific antibody fragments has greatly expanded the use of antibodies [44, 45]. The developments in recombinant antibody technology are built on early, farsighted and pioneering studies that demonstrated that functional chimeric antibodies could be generated using the variable domains from a mouse MAb of known specificity, and expressing them linked to the constant domains of human antibody [46–48]. These studies established that the antigen binding specificity of an antibody could be readily transferred between different antibodies, including antibodies derived from different species. Here we have used the Fv region of mouse MAb D9 to construct (i) chimeric antibodies using the constant regions of rabbit immunoglobulin G (IgG), and (ii) chimeric Fabs using the CH1 (constant heavy 1) and CL (constant light) domains of bovine IgG1. Our results show that the mouse/rabbit D9 chimera performed well in a FMDV ELISA and retained the serotype specificity of the parental MAb D9. In addition, as the resulting antibody has the constant regions of rabbit IgG it can be used directly in the existing FMD diagnostic ELISA. Furthermore, the mouse/rabbit D9 chimera also worked well in other laboratory assays including virus neutralisation tests (VNT), western blot (WB) and confocal microscopy. Cryo-electron microscopy analysis (using the chimeric mouse/bovine Fabs) confirmed engagement with antigenic site 1, and peptide competition studies (using the chimeric mouse/rabbit D9 chimera) identified VP1, D-147 as a novel component of the D9 epitope. Although simple, this approach is not only an effective way to preserve critically important antibodies but also has the potential for future, unlimited generation of recombinant FMDV antibodies (and antibody fragments) for use in FMD diagnosis. Preserving important FMDV antibodies will also negate the need for replacement hybridomas with concomitant positive impacts on the 3Rs (Replacement, Reduction and Refinement) guiding principles.

Materials & methods

Cell lines

Cell culture reagents were all purchased from Sigma. HEK293T cells were provided by Dr Claudine Porta (University of Oxford—obtained October 2014) (source: ATCC, CRL-3216) and cultivated in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) heat inactivated foetal calf serum (FCS) and 2mM L-glutamine. IBRS-2 cells [49] were provided (obtained 1998) by the Food and Agriculture Organisation (FAO) World Reference Laboratory for foot-and-mouth disease (WRL FMD), The Pirbright Institute and cultivated in Glasgow’s modified Eagle’s medium (GMEM) supplemented with 10% adult bovine serum and 2mM L-glutamine. All cell media were supplemented with 100U/ml penicillin and 100μg/ml streptomycin.
Fv cloning and sequencing

The coding sequences for the Fv region (VH [variable heavy] and VL [variable light]) of MAb D9 were cloned by PCR using murine VH and VL specific primer sets essentially as described [50, 51]. The cloned sequences were ligated into fd-tet-DOG1 [52] and confirmed as functionally rearranged VH and VL domains by DNA sequencing. DNA templates were prepared using the Nextera XT DNA Library Prep Kit (Illumina) and data collected on an Illumina MiSeq (Version 2) using a 300 cycle cartridge. MiSeq reads were trimmed to a quality cut off of 30 using Sickle [53]. This was followed by de novo assembly using Velvet [54]. Reads were then aligned to the consensus sequence generated by Velvet using Bowtie2 [55]. The overall alignment rate was 94.09% using 871911 reads.

Construction of antibody/Fab expression vectors

For expression of mouse/rabbit D9 antibodies, cDNA encoding the VH and VL regions of MAb D9 was synthesised using GeneArt (Invitrogen) incorporating EcoRI and XhoI, and EcoRI and BamHI restriction enzyme sites in framework region 1 (FW1) and FW4 for the VH and VL regions respectively. The VH region was cloned into pFUSEss-CHIg-rG’03 (Invivogen) and VL into pFUSE2ss-CLig-rk1 (Invivogen) using the appropriate enzymes to generate plasmids D9VH-rabHC and D9VL-rabLC respectively. For expression of mouse/cattle D9 Fabs, the D9 variable fragments were ligated into mammalian expression vectors containing resident bovine CL and CH1 sequences and a signal sequence. Briefly, the light chain constant region is Bos taurus allotypic variant IGLC3a (Genbank DQ537487 and HQ456934). The CH1 heavy chain is Bos taurus IgG1 (Genbank S82409). Synthetic genes encoding the constant regions were inserted by In-Fusion cloning (Clontech) into PmeI-HindIII cut pOPING-ET [56, 57]. The VH and VL sequences were inserted into the KpnI-PstI (pOPINBOVH) and KpnI-SfoI (pOPINBOVL) restriction sites respectively by In-Fusion cloning. Synthetic genes encoding the candidate D9 variable regions were purchased from IDT Technology as ‘Infusion-ready’ gBlocks and inserted into the pOPIN expression vectors.

Production of antibody chimeras

HEK293T cells were transfected using polyethylenimine (PEI) essentially as described in Longo et al. [58]. Cells were grown in T-175 flasks until 80% confluence and transfected using 17.5 μg DNA for each of the two plasmids (heavy chain and light chain) per flask. Each plasmid was mixed with Opti-MEM (Invitrogen). PEI (Linear, MW 25000 [Polysciences]) (1mg/ml) was used at a ratio of 3:1 to DNA (w/w) and also mixed with Opti-MEM. The plasmids and PEI solutions were mixed (transfection mix) and left at room temperature (RT) for 0.5h. The cells were washed twice with PBS before adding 7ml of transfection mix per flask. The flasks were intermittently rocked for 5h after which 20ml of DMEM (1% FCS v/v) was added and the cells incubated for 4 days before harvesting. Cell supernatants were collected, clarified by centrifugation and stored at +4°C before use. In addition, aliquots of the mouse/rabbit D9 chimeras were subjected to affinity chromatography. Initially, columns (1ml HiTrap Streptavidin HP, [GE Healthcare]) were equilibrated with 5ml binding buffer (20mM sodium phosphate, 150mM NaCl pH7.5) and then coated with C-terminally-biotinylated peptide (Peptide Protein Research Ltd) (amino acid sequence CRYNRNAVPNLRGDLQVLAQK VARTKKKKKK-Biotin; for peptides amino acids are shown using the single letter code) corresponding to the VP1 GH loop of FMDV O1K. The peptide was reconstituted in dH2O and diluted to 1mg/ml in 5ml binding buffer and run twice through the column for coating. Precipitated proteins were removed from the supernatant by centrifugation at 17,700 x g using a JA-10 rotor (Beckman Coulter) and the clarified supernatant was adjusted to pH7.5 before application to the column.
The column was washed with 10ml binding buffer, and then sequentially with wash and elution buffers stepwise at reducing pH values (50mM glycine, 150mM NaCl, pH6, pH5, pH4, pH2.7, pH1.9). Fractions of 900μl were collected from flow-through of elution buffers at pH2.7 and pH1.9, and were collected in tubes containing 100μl 10X neutralisation buffer (1M Tris-HCl, 1.5MNaCl, 1mM EDTA pH8). All solutions were applied to the column using a peristaltic pump and tubing (BioRad) pumping at 1ml/min. Fractions 7 to 12 were pooled before 4-fold concentration and buffer exchange using 10kDa molecular weight cut-off Ultra-15 Centrifugal Filter units (Amicon) into binding buffer. Concentrated antibody was aliquoted and stored at -20°C.

For structural studies the mouse/cattle D9 Fab was expressed by co-transfection of VH and VL vectors into HEK293T cells. Fab proteins were purified from culture supernatants by a combination of immobilised metal affinity and size exclusion chromatography [59].

Production of FMDV empty capsids and inactivated virus

The vaccinia virus expression system and purification of covalent stabilised FMDV O1Manisa (O1Mcc) and A22Iraq (A22cc) empty capsids (ECs) have been described previously in detail [60, 61]. For structural studies, purified inactivated FMDV O1Manisa was produced as described in Kotecha et al [62].

Western blot

To detect rabbit antibody heavy and light chains in the column elution, the fractions were analysed by SDS-PAGE and western blot. A 20μl aliquot of each fraction was denatured and reduced in Red Loading Buffer and DTT (1X final, both NEB) and heated at 96°C for 3 min. The samples were then resolved through 12% Tris-glycine gels and transferred to nitrocellulose membrane (0.45μM, GE Healthcare) using a Mini-Protean tetra cell (BioRad). Membranes were placed in blocking buffer (20mM Tris, 150mM NaCl pH7.6 with 0.1% v/v tween-20 [TBS-T] with 1% bovine serum albumin [BSA] w/v [Melford]) for 1h at RT followed by incubation with goat anti-rabbit IgG (Heavy + Light)—horseradish peroxidase (HRP) (BioRad, 1/2500 in blocking buffer) for 1h at RT then washed three times with TBS-T. West Pico chemiluminescent substrate (Thermo) was added to the membrane and exposures of the membrane were collected and visualised using a G:Box Chemi xx6 (Syngene).

For detection of O1Mcc and A22cc ECs, denatured samples (2μg O1Mcc and 10μg A22cc) were separated on 12% Tris–HCl SDS-polyacrylamide gels (BioRad) and transferred to C membranes (Amersham). After transfer, membranes were blocked overnight at RT using PBS containing 0.1% v/v Tween-20 (PBS-T) with 5% w/v milk powder. The membranes were then incubated with MAb D9 (diluted ascites at 1/1000) [43] in PBS-T with 3% w/v milk powder (Blot A) or with the mouse/rabbit D9 chimera (column elution fraction 8 at 1/10) in PBS-T with 3% w/v milk powder (Blot B) for 1h at RT. Following three washes with PBS-T, membranes were incubated for 1h with an anti-mouse HRP-conjugated secondary antibody (Dako) (Blot A) or an anti-rabbit HRP-conjugated secondary antibody (Dako) (Blot B) both at 1/5000 and the bound antibodies detected as described above.

ELISA

For identifying the mouse/rabbit D9 chimera in elution fractions from the affinity chromatography, plastic 96-well plates (Nunc Maxisorp immunoplates) were incubated with 100μl (2μg/ml) per well of the C-terminally-biotinylate d FMDV O1K VP1 GH loop peptide (described above) in coating buffer (10mM NaHCO₃ buffer, pH 9.6) at 4°C overnight. Wells were washed three times with PBS-T between all incubations. Wells were blocked with 200μl blocking...
buffer (1% w/v BSA in PBS-T) at 37°C for 1h, and incubated either with 100μL of MAb D9 (diluted ascites at 1/100) or concentrated mouse/rabbit D9 chimera (diluted 1:50 in blocking buffer) at 37°C for 1h. Antibody binding was detected by incubation with 100μL of species specific HRP conjugated secondary antibodies (Dako) diluted 1:2000 in blocking buffer at 37°C for 1h. The chromogen development was mediated by the addition of 50μL of HRP substrate (OPD: Sigma). The reaction was stopped after 20 min by addition of 50μL of 1.2M sulfuric acid and the optical density (OD) was measured at 490nm.

To detect immobilised ECs using the mouse/rabbit D9 chimera, plastic 96-well plates (Nunc Maxisorp immunoplates) were incubated with 100μl (1μg/ml) of purified ECs (O1Mcc or A22cc) overnight at 4°C. Blank wells were coated with 100μl of TBS supplemented with 2mM CaCl₂ and 1mM MgCl₂ (TBScm). Wells were washed three times with TBScm between all incubations. Wells were incubated with 200μl of block buffer (BB) (TBScm with 2% w/v BSA) for 1h at RT. ECs were detected by addition of (i) the mouse/rabbit D9 chimera (transfected cell supernatant or concentrated antibody [pooled fractions 7–12] used at 1/10 in BB), (ii) MAb D9 (2.5μg/ml of purified antibody in BB) or (iii) a guinea pig, anti-A₂₂Iraq polyclonal sera (used at 1/1000 in BB) (obtained from the FAO WRL FMD, The Pirbright Institute) for 1h at RT. The wells were then incubated with HRP conjugated secondary antibodies (anti-rabbit-HRP [Bio-Rad], anti-guinea pig-HRP or anti-mouse-HRP [both from Dako]) for 1h at RT at 1/5000 in BB. Wells were washed three times with TBScm and HRP substrate (OPD: Sigma) was added and the OD of the wells was read after 0.5h at 450nm.

For the peptide competition ELISA, peptides (at the indicated concentration) were mixed with the mouse/rabbit D9 chimera for 10 min at RT prior to addition to EC coated wells, and the antibody/peptide mix was incubated on the plate for 20 min rather than 1h. The peptides used were wt (RGDL) (141-VPNLRGDLQVLAQ KVAR-158) corresponding to residues 141 to 158 of the VP1 GH loop of FMDV O₁K and peptides with amino acid substitutions; Peptide L₁₄₈M has a L to Methionine (M) substitution at position 8 of the peptide corresponding to VP1 148; Peptide D₁₄₇E has an D to Glutamic acid (E) substitution at position 7 of the peptide corresponding to VP1 147.

**Virus (VN) neutralisation test**

Tests for FMDV serotype-specific neutralisation by antibodies were carried out in microtitre plates by one-dimensional VN testing using FMDV O₁K and A₂₂Iraq and MAb D9 or the mouse/rabbit D9 chimera (concentrated antibody [pooled fractions 7–12]) starting with 1 in 2 dilution with further 2-fold dilutions following established methodology [42, 63]. Antibody titres were calculated from regression data as the log 10 reciprocal antibody dilution required for 50% neutralisation of 100 tissue culture infective units of virus (log 10SN 50/100 TCID 50). Tests were carried out in duplicate.

**Immunofluorescence confocal microscopy**

IBRS-2 cells on 13-mm glass coverslips (VWR) were mock treated or infected with FMDV O₁K for 3.75 hours and then washed with PBS and fixed with 4% paraformaldehyde for 40 min at RT. The cells were then permeabilised for 20 min with 0.1% v/v Triton X-100 (Sigma) prepared in blocking buffer (Tris-buffered saline supplemented with 1mM CaCl₂, 0.5mM MgCl₂, 10% v/v normal goat serum, and 1% v/v fish skin gelatin). The cells were then incubated with a primary antibody (MAb D9 or mouse/rabbit D9 chimera) for 1h at RT. The mouse/rabbit D9 chimera was used as crude cell supernatant diluted 1:1 with blocking buffer and MAb D9 at 2.5μg/ml of purified antibody in blocking buffer. The cells were then washed and incubated with Alexa-Fluor-conjugated secondary antibodies (goat anti-mouse IgG
Alexa-568 and goat anti-rabbit Alexa-488 conjugated; both from Thermo Fisher) diluted 1/200 in blocking buffer for 45 min at RT. After washing, the cells were mounted using Vectashield mounting medium with DAPI (4,6-diamidino-2-phenylindole) (Vector Labs) and the coverslips sealed with nail varnish. All data were collected sequentially, to eliminate cross talk of the fluorescent dyes, using a Leica TCS/SP2 confocal laser scanning microscope. To eliminate non-specific binding of the secondary conjugated antibodies the species specificity of the secondary antibodies was confirmed as follows. When cells were incubated with a primary antibody they were incubated with both secondary antibodies simultaneously and data collected for both the red (568) and green (488) channels. When the primary antibody was MAb D9 only the red channel was positive; when the primary antibody was the rabbit D9 chimera only the green channel was positive.

Cryo-electron microscopy

We formed the FMDV-D9 complex for cryo-EM by incubation of the chimeric mouse/cattle D9 Fab with purified inactivated FMDV O Manisa overnight at 4 °C, in HEPES buffer pH 8. The concentration of virus was 0.5 mg/ml and the Fab was present in 300 times molar excess in terms of antibody concentration compared to particle concentration (this corresponds to 5 times excess assuming 60 binding sites per particle). The mouse/cattle D9 Fab was used as it was readily purified and was expected to give better structural data than a full-length antibody. The incubations contained five Fab molecules per binding site (assuming 60 binding sites per capsid). A 4 μl aliquot of the mixture was applied on a glow-discharged holey carbon-coated copper grid (C-flat, CF-2/1-2C [Protochips]), the grid was blotted for 3s in 90% relative humidity and plunge-frozen in liquid ethane using a Vitrobot mark IV (FEI).

Cryo-EM data were collected using a Tecnai F30 'Polara' microscope (FEI) operated at 300 kV, equipped with an energy filter (GIF Quantum [Gatan]) operating in zero-loss mode (20-eV energy selecting slit width), and a direct electron detector (K2 Summit [Gatan]). Data were collected as movies (25 frames, each 0.2s) in single electron counting mode with SerialEM [64] using a defocus range of 1.5–3.0 μm and at calibrated magnification of ×37,037, corresponding to pixel size of 1.35 Å. Dose rate at detector pixel was 8 e−/pixel/s, resulting in total electron dose of 25 e−/Å² in the specimen.

Frames from each movie were aligned and averaged to produce drift-corrected micrographs [65] and the contrast transfer function parameters estimated using CTFFIND4 [66]. Micrographs showing signs of astigmatism or significant drift were discarded. Particles were selected using EMAN2 [67]. Structures were determined with Relion 1.4 following the so-called gold-standard refinement procedure to prevent overfitting [68] with icosahedral symmetry applied. Reference-free 2D and template-based 3D classification was used to select the most ordered fraction of particles. The X-ray structure of native FMDV O Manisa (PDB code: 5AC9) [60] was low-pass-filtered to 50-Å resolution and used as an initial template for 3D classification and refinement. A total of 1003 particles selected from a total of 1025 micrographs were used to calculate the final density map at 3.5 Å resolution (virus), as estimated by Fourier shell correlation (FSC). Final maps were sharpened by applying an inverse B-factor and the effect of masking was taken into account by high-resolution phase randomization.

Results

Sequence and characterisation of the Fv region of MAb D9

The Fv region of antibodies is formed by VH and VL domains, which associate by non-covalent interactions to form the antigen-combining site (ACS). The ACS is formed by the six complementarity-determining regions (CDRs); three from the VL and VH domains, respectively.
which are separated by the framework regions [69]. The boundaries of the CDRs are commonly assigned using either the Kabat or Chothia numbering schemes [69–71]. The former assigns CDRs on the basis of sequence variation across the V domains while the Chothia scheme is based on analyses of antibody structures. Fig 1 shows the amino acid sequence of the VH and VL domains of MAb D9 and CDR boundary assignment using either Chothia or Kabat numbering. Fig 1 also includes the amino acid sequence for the VH and VL domains of MAb SD6, which recognises the same antigenic site as MAb D9 but on a different FMDV serotype (FMDV C-S8c1) [72]. The antigenic site recognised by MAb D9 and SD6 are both mapped to the GH loop of VP1 (which are referred to as antigenic site 1 and antigenic site A for FMDV type O and type C, respectively) but have different lengths and sequences [34, 72, 73]. A number of studies have shown that five of the CDRs (L1-3, H1 and H2) adopt one of a small number of main chain conformations termed canonical structures [74–82]. These play a significant role in determining the shape of the ACS. The topography of the ACS often correlates with antigen type and deep pockets and grooves are characteristic of antibodies that bind haptens or peptides, respectively, while antibodies that bind to proteins tend to have relatively flat combining sites [83, 84]. The mean CDR lengths (using the Kabat definitions) of mouse anti-peptide antibodies have been determined as 14.7 (L1), 7 (L2), 8.9 (L3), 5.2 (H1), 16.9 (H2) and 8.8 (H3) [83]. Fig 1 shows that the CDR lengths are similar for MAb D9 and SD6 (the CDR lengths are identical for the VH domain, although the CDR1 of the VL domain is two residues longer in D9 than SD6). The crystal structure of the Fab fragment of MAb SD6 has been determined in a complex with a 15-mer peptide representing the epitope recognised (antigenic site A). The Fab/peptide structure shows that, consistent with the length of the CDRs and the above characteristics of peptide binding antibodies, the CDRs of SD6 form a
groove that is occupied by the peptide [85]. These observations might suggest that the ACS of D9 will also be a groove that can accommodate the peptide.

**Structural modelling of D9 and analysis of capsid binding**

We noted that although SD6 is similar in sequence to MAb D9 other structures in the protein data bank are even more similar. We therefore used the SAbPred server to model the D9 VH/VL structure [86]. The resultant model is indeed close to SD6, 97% of the model Cα atoms could be superimposed with RMSD 0.7 Å using program SHP [87], and the molecule contains a similar binding groove to SD6 (Fig 2). However, the first residue of the VH CDR3 is altered from R in SD6 to E in D9. In SD6 this R forms a key interaction with the D-147 side chain of the RGD integrin binding motif of VP1 (Fig 2). In contrast the acid side chain in D9 is incapable of such favourable interactions. This might suggest a different engagement of the peptide.

**Fig 2. MAb SD6 and modelling of D9 variable domains.** Cartoon depiction showing SD6 variable domains in grey and modelled D9 VH domain in orange and VL domain in blue. The peptide bound to SD6 is shown in red with the side chains for the RGD motif and the L residues at 144 and 148 drawn in stick representation coloured by atom. R/E indicates the position of the first residue of CDR3, which is an R in SD6 and an E in D9. In the FMDV/SD6 complex the R interacts with VP1 D-147 (interactions are represented by yellow broken lines).

https://doi.org/10.1371/journal.pone.0201853.g002
in the groove, and hence a different pose of the antibody on the virus. This notion is supported by the identification of VP1 K-154 as a component of the epitope for D9 [33, 39], since in the SD6 complex with type C FMDV the homologous residue of VP1 (Threonine [T]-150) is not in contact with the antibody [85].

To investigate the mode of interaction further, recombinant mouse/cattle D9 Fab was produced (see Methods). Unfortunately, the level of expression was too low to allow crystallographic structure determination, however it was sufficient to obtain the structure of a virus-Fab complex by cryo-EM (Fig 3). The structure of the virus capsid is generally well resolved, whilst the electron potential map for the bound Fab is diffuse. However by superimposing the FMDV-SD6 complex [88] onto the EM map it is clear that, similar to SD6, the Fv region of D9 engages with the VP1 GH loop in the ‘up’ conformation, however the pose of the antibody on the virus surface is clearly different, with D9 binding in a more upright configuration (Fig 3).

Thus the exposed VP1 GH loop, which comprises a major antigenic site, seems to be presented in a consistent but flexible configuration similar to that observed on FMDV binding to its

![Cryo-EM complex of D9 with FMDV O1 Manisa.](https://doi.org/10.1371/journal.pone.0201853.g003)
integrin receptor [62]. Furthermore the FMDV VP1 GH loop appears to select mouse antibodies bearing a similar groove, however the specific interactions and hence the orientation of the peptide within the groove appears to vary.

**Production and characterisation of a mouse/rabbit chimeric antibody using the Fv region of MAb D9**

To produce a mouse/rabbit chimera, cDNA for the VH and VL domains of MAb D9 was cloned into mammalian expression vectors that encode for a signal peptide and the constant regions of either the heavy or light chains of rabbit IgG (see Methods). This produced plasmids that express the D9 VH in frame with the rabbit IgG heavy-chain constant regions (D9VH-rabHC), or D9 VL in frame with rabbit IgG light-chain constant regions (D9VL-rabLC). HEK293T cells were co-transfected with these plasmids or transfected with the plasmids individually. Transfected cell supernatants were subsequently harvested and the mouse/rabbit D9 chimera subjected to affinity chromatography. Fig 4 shows western blots for the elution fractions probed for the constant regions of rabbit IgG, heavy (Fig 4A) or light chains (Fig 4B). This shows that although bands could not be detected in the crude cell supernatant, bands of the expected size for full-length heavy and light antibody chains were detected in the recovered fractions. This is likely due to a low antibody concentration in the supernatants and indicates that the affinity chromatography results in a greater antibody concentration. Fig 4C shows an ELISA using aliquots of the fractions to detect immobilised VP1 GH loop peptide. This showed a good agreement between the amount of heavy and light chain detected in each

![Western Blot](https://doi.org/10.1371/journal.pone.0201853.g004)

**Fig 4. Initial characterisation of the mouse/rabbit D9 chimera.** Panels A and B show a western blot to detect rabbit IgG heavy (A) and light chains (B) in the elution fractions from affinity chromatography of the mouse/rabbit D9 chimera. Panel C shows an ELISA using the elution fractions (E6-12) to detect immobilised FMDV O1K VP1 GH loop peptide. SN = transfected cell culture supernatant; FT = column flow-through; W = column wash; E6-12 = elution fractions 6–12. The OD of the wells was read at 490nm. Shown is the mean and SD of duplicate samples.

https://doi.org/10.1371/journal.pone.0201853.g004
fraction (Fig 4A and 4B) and the ELISA signal (Fig 4C) with the exception of E11 where the ELISA signal was similar to the unprocessed cell supernatant. This apparent loss of function could be due to some denaturation of the antibody in the later elution fractions due to a lower pH of the elution buffer.

MAb D9 is specific for type O FMDV and does not recognise type A viruses [89]. Next we tested if the mouse/rabbit D9 chimera retained this specificity for FMDV. Fig 5 shows that for immobilised type O capsids, but not type A, a positive ELISA signal was detected when using the mouse/rabbit D9 chimera as the detecting antibody. Positive signals were obtained when using the concentrated mouse/rabbit D9 chimera or culture supernatants from cells co-transfected with heavy and light chain expression vectors, but not when using cell culture supernatants from cells transfected with either heavy or light chain expression vectors individually. As expected, MAb D9 and a guinea pig, anti-A22 Iraq sera gave a positive signal for immobilised type O and type A capsid respectively. This analysis shows that the mouse/rabbit D9 chimera retains specificity for type O FMDV capsids and can be used to detect FMDV either as a crude cell supernatant or after affinity chromatography and concentration.

The epitope for MAb D9 resides on the GH loop of VP1 [33, 39] and MAb D9 has been reported to bind a peptide corresponding to this region of type O FMDV [89]. To confirm the specificity of the mouse/rabbit D9 chimera for the VP1 GH loop we carried out a competition ELISA using peptides corresponding to the D9 epitope. Fig 6 shows that a 17-mer peptide with the sequence (141-VPNLRGDLQVLAQKVAR-158) of the VP1 GH loop of FMDV O1K was able to inhibit binding of the mouse/rabbit D9 chimera to immobilised FMDV capsid in a concentration dependent manner. The L at VP1 148 has been identified as a critical part of the epitope recognised by MAb D9. Consistent with this observation, a peptide based on the above 17-mer with a L to M change (i.e. equivalent to 148 in VP1) did not inhibit binding of the
mouse/rabbit D9 chimera to O₁Manisa EC. In MAb SD6 this residue occupies a hydrophobic portion of the binding groove formed by CDR3, and it seems likely that this is also true for D9. Interestingly, a second peptide with a D to E substitution at the integrin-binding RGD tri-peptide (equivalent to 147 in VP1) also failed to inhibit binding of the mouse/rabbit D9 chimera. This suggests that the D at position 147 is also critical for D9 binding to FMDV. As noted above, this interaction is also key for MAb SD6, although the interacting residue, an R in SD6, is an E in D9. Thus the mode of engagement of the peptide within the groove must be significantly different to facilitate a more favourable interaction.

MAb D9 has been reported to neutralise FMDV infectivity. Therefore we also tested if the mouse/rabbit D9 chimera retained this ability. Fig 7 shows that MAb D9 and the concentrated mouse/rabbit D9 chimera both neutralised type O FMDV, thereby confirming that the chimera retained the neutralising capability and specificity of MAb D9 for type O FMDV.

We also tested the mouse/rabbit D9 chimera as the detecting antibody in a western blot (Fig 8). Consistent with the above results showing that the mouse/rabbit D9 chimera retains the FMDV serotype specificity of the parental mouse antibody, the chimeric antibody identified a band the correct size for VP1 for type O but not type A capsids.
MAb D9 has also been used to detect FMDV capsids by confocal microscopy [90]. Fig 9 shows that the mouse/rabbit D9 chimera can also be used for this purpose. Fig 9A and 9B show mock-infected cells that were incubated simultaneously with the mouse/rabbit D9 chimera and MAb D9 followed by both secondary antibodies (goat anti-mouse IgG Alexa-568

![Log VNT Titer](image)

**Fig 7. FMDV serotype-specific neutralisation by the mouse/rabbit D9 chimera.** Shown are the virus neutralisation titres for MAb D9 and the concentrated mouse/rabbit D9 chimera (chimeric D9, pooled fractions 7–12). Antibody titres were calculated from regression data as the log 10 reciprocal antibody dilution required for 50% neutralisation of 100 tissue culture infective units of virus (log 10SN 50/100 TCID 50). Shown is the mean and SD of duplicate samples. O1K = FMDV O1 Kaufbeuren; A22 = A22 Iraq.

https://doi.org/10.1371/journal.pone.0201853.g007

MAb D9 has also been used to detect FMDV capsids by confocal microscopy [90]. Fig 9 shows that the mouse/rabbit D9 chimera can also be used for this purpose. Fig 9A and 9B show mock-infected cells that were incubated simultaneously with the mouse/rabbit D9 chimera and MAb D9 followed by both secondary antibodies (goat anti-mouse IgG Alexa-568

![A & B](image)

**Fig 8. The specificity of the mouse/rabbit D9 chimera for FMDV capsid determined by western blot.** Detection of EC (O1Mcc and A22cc) using MAb D9 (diluted ascites at 1/1000) (A) or the mouse/rabbit D9 chimera (column elution fraction 8 at 1/10) (B).

https://doi.org/10.1371/journal.pone.0201853.g008
Fig 9. The mouse/rabbit D9 chimera identifies VP1 in FMDV infected cells. IBRS-2 cells were mock-treated or infected with type O FMDV. Panels A and B show mock cells incubated with chimeric D9 and MAb D9 simultaneously followed by the goat anti-mouse IgG Alexa-568 and goat anti-rabbit Alexa-488 conjugated secondary antibodies. Panels C and D show infected cells incubated with MAb D9 and both secondary antibodies, and data collection for the red (C) and green (D) channels. Panels E and F show infected cells incubated with the chimeric D9 and both secondary antibodies, and data collection for the red (E) and green (F) channels. Panels G-I show FMDV infected cells incubated simultaneously with chimeric D9 and MAb D9 followed by both secondary antibodies. Panel G shows data collected for MAb D9 and panel H for the chimeric antibody, while panel I shows the merged image (of panels G and H). Panels A and B, C and D, E and F, and G and H, show the same cells imaged using the red or green channels. Scale bar = 10μM.

https://doi.org/10.1371/journal.pone.0201853.g009
and goat anti-rabbit Alexa-488), and that no signal could be detected. Fig 9C and 9D show FMDV infected cells that were incubated with MAb D9 followed by both secondary antibodies and that a signal (red) could only be detected for the anti-mouse secondary (and not for the anti-rabbit secondary), while 9E and 9F show FMDV infected cells that were incubated with the mouse/rabbit D9 chimera followed by both secondary antibodies and that a signal (green) could only be detected using the anti-rabbit secondary. Fig 9G–9I show FMDV infected cells that were incubated simultaneously with both the chimeric antibody and MAb D9 followed by both secondary antibodies. Fig 9G shows data collected for MAb D9 and 9H for the mouse/rabbit D9 chimera, while 9I shows the merged image (of 9G and 9H) and that MAb D9 and the chimeric antibody give near complete co-localisation for VP1. These data show that the mouse/rabbit D9 chimera can be used to detect FMDV capsid proteins in infected cells and confirm the species specificity of the secondary antibodies.

Discussion

The main disadvantage of the current FMD diagnostic ELISA is that replacement stocks of antibody reagents need to be generated [20]. To counter this limitation, we have previously shown that recombinant integrin αvβ6 can be used as a ‘universal’ capture ligand for all FMDV serotypes [20, 91]. In addition, MAbs have been used in combination with the integrin [21] and ultimately it is envisaged that the integrin/MAb ELISA could reduce the need to generate new polyclonal sera. However, hybridomas can suffer stability problems (see Introduction) and recently an FMDV pan-reactive antibody was lost due to problems associated with hybridoma maintenance [28]. Here, using a MAb (MAb D9) to type O FMDV, we demonstrate that cloning the Fv regions can preserve critical FMDV MAbs. The resulting mouse/rabbit D9 chimera retained the FMDV serotype-specificity of the parental MAb D9 and performed well in a FMDV detection ELISA. Furthermore, the chimera is readily produced by simple cell transfection and overcomes the need for continual maintenance and storage of the D9 hybridoma. In addition, the chimera could be used without extensive purification thereby potentially saving time and costs of generation, and by creating a rabbit version of MAb D9, it has the potential to be used in existing FMD diagnostic ELISA tests. In addition, the mouse/rabbit D9 chimera also worked well in other routine antibody-based methods including virus neutralisation tests, immunofluorescence confocal microscopy and western blotting expanding the potential uses of the antibody.

The epitope for MAb D9 resides on the VP1 GH loop (residues 136–158) and the L at residue 148 has been identified as a critical part of the epitope and was changed to R in D9 MAb escape mutant viruses [33, 39]. The residue at VP1 148 is also important for integrin recognition and is part of an extended binding site for αvβ6 that includes the integrin-binding ‘core’ RGD and the residues at positions RGD+1 and RGD+4 [92, 93]. Regardless of serotype, integrin αvβ6 is the receptor for all FMDV field strains and in FMDV field strains the residue at VP1 148 is usually L, R or occasionally M [90, 94]. Thus the L to R change in the MAb D9 escape mutant viruses was likely driven by a combination of the need to escape antibody neutralisation and also to preserve binding to integrin receptors [92, 93]. MAb D9 has been reported to bind a peptide corresponding to the VP1 GH loop of type O FMDV [89]. Consistent with this observation, our study shows that a 17-mer peptide with the sequence (141-VPNLRGDLQVLAQKVAR-158) of the VP1 GH loop of FMDV O K inhibited binding of the mouse/rabbit D9 chimera to immobilised FMDV EC (O1Mcc). Furthermore, as expected from the critical role of L-148 in the D9 epitope [33, 39], a peptide with an L to M change at this site did not inhibit binding of the mouse/ D9 chimera. However, our results also identified D-147 as a novel residue of the D9 epitope as a peptide with an E substitution at this
site also failed to inhibit binding. It is likely that substitutions at VP1 D-147 were not seen in MAb D9 escape mutant viruses as this residue is within the critical RGD integrin-binding tripeptide and changes at this site would render the virus non-infectious due to a failure to bind integrins [94, 95]. Binding to the GH loop of VP1 was confirmed by cryo-EM structure determination of an FMDV-D9 complex. The structure is consistent with the GH loop being presented in an ‘up’ conformation to facilitate binding within a groove on the antibody. Furthermore, comparison with another FMDV GH loop binding antibody (SD6) showed that interactions with the VP1 GH are broadly recapitulated, although the ‘pose’ of the antibody on the virus surface, is somewhat different. The interaction of D-147 with D9 must differ since the R in SD6, at the beginning of the VH CDR3, which forms key interactions with D-147 is changed to an E in D9, so that the role of this antibody residue must be substituted by another. Collectively, our studies have revealed an important role for VP1 D-147 in antibody binding, which has until now been masked by the critical role of D-147 in receptor interactions and therefore virus viability, and suggest that interactions with D-147 are likely to be a key determinant of the mode of engagement of the GH loop with antibodies.

In conclusion, using the Fv region of MAb D9 we have used established methods to generate recombinant anti-FMDV chimeric antibodies that can be produced by transient cell transfection and used in a number of standard laboratory methods including an ELISA to detect FMDV. In addition, peptide competition studies identified VP1 D-147 as a critical residue of the D9 epitope, and suggest it may be a key interaction for many antibodies binding at this site. Although validation studies are needed to fully explore the diagnostic potential of such recombinant antibodies, this approach can be used to preserve critical antibodies for FMD diagnosis.

**Author Contributions**

**Conceptualization:** Gareth Shimmon, Toby J. Tuthill, Donald P. King, Andrew M. Q. King, Ray Owens, Elizabeth E. Fry, David I. Stuart, Alison Burman, Terry Jackson.

**Data curation:** Gareth Shimmon, Abhay Kotecha, Jingshan Ren, Amin S. Asfor, Joseph Newman, Stephen Berryman, Eleanor M. Cottam, Sarah Gold, Ray Owens, Elizabeth E. Fry, David I. Stuart, Alison Burman.

**Formal analysis:** Gareth Shimmon, Abhay Kotecha, Jingshan Ren, Amin S. Asfor, Joseph Newman, Stephen Berryman, Eleanor M. Cottam, Sarah Gold, Ray Owens, Elizabeth E. Fry, David I. Stuart, Alison Burman.

**Funding acquisition:** Toby J. Tuthill, Donald P. King, Andrew M. Q. King, David I. Stuart, Terry Jackson.

**Investigation:** Gareth Shimmon, Abhay Kotecha, Jingshan Ren, Amin S. Asfor, Joseph Newman, Stephen Berryman, Eleanor M. Cottam, Sarah Gold, Toby J. Tuthill, Donald P. King, Emiliana Brocchi, Andrew M. Q. King, Ray Owens, Elizabeth E. Fry, David I. Stuart, Alison Burman, Terry Jackson.

**Methodology:** Gareth Shimmon, Abhay Kotecha, Jingshan Ren, Amin S. Asfor, Joseph Newman, Stephen Berryman, Eleanor M. Cottam, Sarah Gold, Toby J. Tuthill, Ray Owens, Elizabeth E. Fry, David I. Stuart, Alison Burman, Terry Jackson.

**Project administration:** Gareth Shimmon, David I. Stuart, Terry Jackson.

**Resources:** Toby J. Tuthill, Donald P. King, Emiliana Brocchi, Andrew M. Q. King, David I. Stuart, Terry Jackson.
Software: Abhay Kotecha, Jingshan Ren, Eleanor M. Cottam, Ray Owens, Elizabeth E. Fry, David I. Stuart.

Supervision: Toby J. Tuthill, Donald P. King, Andrew M. Q. King, David I. Stuart, Terry Jackson.

Validation: Gareth Shimmon, Abhay Kotecha, Jingshan Ren, Amin S. Asfor, Joseph Newman, Stephen Berryman, Eleanor M. Cottam, Sarah Gold, Ray Owens, Elizabeth E. Fry, David I. Stuart, Alison Burman, Terry Jackson.

Visualization: Gareth Shimmon, Jingshan Ren, Amin S. Asfor, Joseph Newman, Stephen Berryman, Eleanor M. Cottam, Sarah Gold, Toby J. Tuthill, Donald P. King, Andrew M. Q. King, Ray Owens, Elizabeth E. Fry, David I. Stuart, Alison Burman, Terry Jackson.

Writing – original draft: Gareth Shimmon, Abhay Kotecha, Jingshan Ren, Amin S. Asfor, Joseph Newman, Stephen Berryman, Sarah Gold, Toby J. Tuthill, Donald P. King, Ray Owens, Elizabeth E. Fry, David I. Stuart, Alison Burman, Terry Jackson.

Writing – review & editing: Gareth Shimmon, David I. Stuart, Terry Jackson.

References

1. Arzt J, Baxt B, Grubman MJ, Jackson T, Juleff N, Rhyan J, et al. The pathogenesis of foot-and-mouth disease II: viral pathways in swine, small ruminants, and wildlife; myotropism, chronic syndromes, and molecular virus-host interactions. Transboundary and emerging diseases. 2011; 58(4):305–26. https://doi.org/10.1111/j.1865-1682.2011.01236.x PMID: 21672184.

2. Knight-Jones TJ, Rushton J. The economic impacts of foot and mouth disease—what are they, how big are they and where do they occur? Preventive veterinary medicine. 2013; 112(3–4):161–73. https://doi.org/10.1016/j.prevetmed.2013.07.013 PMID: 23958457.

3. Jackson T, King AM, Stuart DI, Fry E. Structure and receptor binding. Virus research. 2003; 91(1):33–46. PMID: 12527436.

4. Rowlands DJ, Cartwright B, Brown F. Evidence for an internal antigen in foot-and-mouth disease virus. The Journal of general virology. 1969; 4(4):479–87. https://doi.org/10.1099/0022-1317-4-4-479 PMID: 4308741.

5. Talbot P, Brown F. A model for foot-and-mouth disease virus. The Journal of general virology. 1972; 15 (2):163–9. https://doi.org/10.1099/0022-1317-15-2-163 PMID: 4338333.

6. Acharya R, Fry E, Stuart D, Fox G, Rowlands D, Brown F. The three-dimensional structure of foot-and-mouth disease virus at 2.9 A resolution. Nature. 1989; 337(6209):709–16. https://doi.org/10.1038/337709a0 PMID: 2537470.

7. Baxt B, Becker Y. The effect of peptides containing the arginine-glycine-aspartic acid sequence on the adsorption of foot-and-mouth disease virus to tissue culture cells. Virus genes. 1990; 4(1):73–83. PMID: 2168107.

8. Bernstein A, Roivainen M, Hovi T, Mason PW, Baxt B. Antibodies to the vitronectin receptor (integrin alpha V beta 3) inhibit binding and infection of foot-and-mouth disease virus to cultured cells. Journal of virology. 1995; 69(4):2664–6. PMID: 7533862.

9. Fox G, Parry NR, Barnett PV, McGinn B, Rowlands DJ, Brown F. The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid). The Journal of general virology. 1989; 70 (Pt 3):625–37. https://doi.org/10.1099/0022-1317-70-3-625 PMID: 2543752.

10. Jackson T, Sheppard D, Denyer M, Blakemore W, King AM. The epithelial integrin alphavbeta6 is a receptor for foot-and-mouth disease virus. Journal of virology. 2000; 74(11):4949–56. PMID: 10799568.

11. Brooksby JB. The virus of foot-and-mouth disease. Advances in virus research. 1958; 5:1–37. PMID: 13508401.

12. Domingo E, Escarmis C, Baranowski E, Ruiz-Jarabo CM, Carrillo E, Nunez JL, et al. Evolution of foot-and-mouth disease virus. Virus research. 2003; 91(1):47–63. PMID: 12527437.

13. Rodriguez LL, Gay CG. Development of vaccines toward the global control and eradication of foot-and-mouth disease. Expert review of vaccines. 2011; 10(3):377–87. https://doi.org/10.1586/erv.11.4 PMID: 21434805.
14. Roeder PL, Le Blanc Smith PM. Detection and typing of foot-and-mouth disease virus by enzyme-linked immunosorbent assay: a sensitive, rapid and reliable technique for primary diagnosis. Research in veterinary science. 1987; 43(2):225–32. PMID: 2825310.

15. Ferris NP, Dawson M. Routine application of enzyme-linked immunosorbent assay in comparison with complement fixation for the diagnosis of foot-and-mouth and swine vesicular diseases. Veterinary microbiology. 1988; 16(3):201–9. PMID: 3376418.

16. Goller KV, Dill V, Madi M, Martin P, Van der Stede Y, Vandenberge V, et al. Rapid and simple detection of foot-and-mouth disease virus: Evaluation of a cartridge-based molecular detection system for use in basic laboratories. Transboundary and emerging diseases. 2018; 65(2):578–84. Epub 2017/11/11. https://doi.org/10.1111/tbed.12744 PMID: 29124905.

17. Howson ELA, Armsbony A, Chepkwoy E, Kasanga CJ, Kandusi S, et al. Direct detection and characterization of foot-and-mouth disease virus in East Africa using a field-ready real-time PCR platform. Transboundary and emerging diseases. 2018; 65(1):221–31. Epub 2017/08/02. https://doi.org/10.1111/tbed.12684 PMID: 28758346.

18. Jamal SM, Belsham GJ. Foot-and-mouth disease: past, present and future. Veterinary research. 2013; 44:116. Epub 2013/12/07. https://doi.org/10.1186/1297-9616-44-116 PMID: 24308718.

19. Knight-Jones TJ, Robinson L, Charleston B, Rodriguez LL, Gay CG, Sumpton KJ, et al. Global Foot-and-Mouth Disease Research Update and Gap Analysis: 4—Diagonstics. Transboundary and emerging diseases. 2016; 63 Suppl 1:42–8. Epub 2016/06/21. https://doi.org/10.1111/tbed.12523 PMID: 27320165.

20. Ferris NP, Abrescia NG, Staur DJ, Burman A, King DP, et al. Utility of recombinant integrin alpha v beta6 as a capture reagent in immunoassays for the diagnosis of foot-and-mouth disease. Journal of virological methods. 2005; 127(1):69–79. https://doi.org/10.1016/j.jviromet.2005.02.014 PMID: 15893568.

21. Ferris NP, Grazzioli S, Hutchings GH, Brocchi E. Validation of a recombinant integrin alphavbeta6/mamnclonal antibody based antigen ELISA for the diagnosis of foot-and-mouth disease. Journal of virological methods. 2011; 175(2):253–60. https://doi.org/10.1016/j.jviromet.2011.05.026 PMID: 21635921.

22. Ferris N, Reid S, Hutchings G, Kitching P, Danks C, Barker I, et al. Pen-side test for investigating FMD. The Veterinary record. 2001; 148(26):823–4. PMID: 11467616.

23. Ferris NP, Nordengrahn A, Hutchings GH, Paton DJ, Kristerstson T, Brocchi E, et al. Development and laboratory validation of a lateral flow device for the detection of serotype SAT 2 foot-and-mouth disease viruses in clinical samples. Journal of virological methods. 2010; 163(2):474–6. https://doi.org/10.1016/j.jviromet.2009.09.022 PMID: 19815031.

24. Reid SM, Ferris NP, Bruning A, Hutchings GH, Kowalska Z, Akerbliom L. Development of a rapid chromatographic strip test for the pen-side detection of foot-and-mouth disease virus antigen. Journal of virological methods. 2001; 96(2):189–202. PMID: 11445149.

25. Chuck AS, Palsson BO. Population balance between producing and nonproducing hybridoma clones is very sensitive to serum level, state of inoculum, and medium composition. Biotechnol Bioeng. 1992; 39(3):354–60. Epub 1992/02/05. https://doi.org/10.1002/bit.260390315 PMID: 18600953.

26. Couture ML, Heath CA. Relationship between loss of heavy chains and the appearance of nonproducing hybridomas. Biotechnol Bioeng. 1995; 47(2):270–5. Epub 1995/07/20. https://doi.org/10.1002/bit.260470219 PMID: 18623401.

27. Merritt SE, Palsson BO. Loss of antibody productivity is highly reproducible in multiple hybridoma subclones. Biotechnol Bioeng. 1993; 42(2):247–50. Epub 1993/06/20. https://doi.org/10.1002/bit.260420213 PMID: 18612986.

28. Ferris NP, Nordengrahn A, Hutchings GH, Reid SM, King DP, Ebert K, et al. Development and laboratory validation of a lateral flow device for the detection of foot-and-mouth disease virus in clinical samples. Journal of virological methods. 2009; 158(4):10–7. https://doi.org/10.1016/j.jviromet.2009.09.014 PMID: 18848845.

29. Barnett PV, Ouldridge EJ, Rowlands DJ, Brown F, Parry NR. Neutralizing epitopes of type O foot-and-mouth disease virus. I. Identification and characterization of three functionally independent, conformational sites. The Journal of general virology. 1989; 70 (Pt 6):1483–91. https://doi.org/10.1099/0022-1317-70-6-1483 PMID: 2471811.

30. Baxt B, Vakhtaria V, Moore DM, Franke AJ, Morgan DO. Analysis of neutralizing antigenic sites on the surface of type A12 foot-and-mouth disease virus. Journal of virology. 1989; 63(5):2143–51. PMID: 2467993.

31. Bolwell C, Clarke BE, Parry NR, Ouldridge EJ, Brown F, Rowslan D. Epitope mapping of foot-and-mouth disease virus with neutralizing monoclonal antibodies. The Journal of general virology. 1989; 70 (Pt 1):59–68. https://doi.org/10.1099/0022-1317-70-1-59 PMID: 2471783.
32. Crowther JR, Farias S, Carpenter WC, Samuel AR. Identification of a fifth neutralizable site on type O foot-and-mouth disease virus following characterization of single and quintuple monoclonal antibody escape mutants. The Journal of general virology. 1993; 74 (Pt 8):1547–53. https://doi.org/10.1099/0022-1317-74-8-1547 PMID: 8393912.

33. Kitson JD, McCahon D, Belsham GJ. Sequence analysis of monoclonal antibody resistant mutants of type O foot and mouth disease virus: evidence for the involvement of the three surface exposed capsid proteins in four antigenic sites. Virology. 1990; 179(1):26–34. PMID: 1699353.

34. Mateu MG, Martinez MA, Capucci L, Andreu D, Giralt E, Sobrino F, et al. A single amino acid substitution affects multiple overlapping epitopes in the major antigenic site of foot-and-mouth disease virus of serotype C. The Journal of general virology. 1990; 71 (Pt 3):629–37. https://doi.org/10.1099/0022-1317-71-3-629 PMID: 1690261.

35. McCahon D, Crowther JR, Belsham GJ, Kitson JD, Duchesne M, Have P, et al. Evidence for at least four antigenic sites on type O foot-and-mouth disease virus involved in neutralization; identification by single and multiple site monoclonal antibody-resistant mutants. The Journal of general virology. 1989; 70 (Pt 3):639–45. https://doi.org/10.1099/0022-1317-70-3-639 PMID: 241793.

36. Pfaff E, Thiel HJ, Beck E, Stromhaier K, Schaller H. Analysis of neutralizing epitopes on foot-and-mouth disease virus. Journal of virology. 1988; 62(6):2033–40. PMID: 2835057.

37. Stave JW, Card JL, Morgan DO, Vakharia VN. Neutralization sites of type O1 foot-and-mouth disease virus defined by monoclonal antibodies and neutralization-escape virus variants. Virology. 1988; 162 (1):21–9. PMID: 2827379.

38. Thomas AA, Woortmeijer RJ, Puijk W, Barteling SJ. Antigenic sites on foot-and-mouth disease virus type A10. Journal of virology. 1988; 62(8):2782–9. PMID: 2455819.

39. Xie QC, McCahon D, Crowther JR, Belsham GJ, McCullough KC. Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites. The Journal of general virology. 1987; 68 (Pt 16):1637–47. https://doi.org/10.1099/0022-1317-68-6-1637 PMID: 2438378.

40. Logan D, Abu-Ghazaleh R, Blakemore W, Curry S, Jackson T, King A, et al. Structure of a major immunogenic site on foot-and-mouth disease virus. Nature. 1993; 362 (6420):566–8. https://doi.org/10.1038/362566a0 PMID: 8385272.

41. Rowlands D, Logan D, Abu-Ghazaleh R, Blakemore W, Curry S, Jackson T, et al. The structure of an immunodominant loop on foot and mouth disease virus, serotype O1, determined under reducing conditions. Archives of virology Supplementum. 1994; 9:51–8. PMID: 8032279.

42. Asfor AS, Upadhyaya S, Knowles NJ, King DP, Paton DJ, Mahapatra M. Novel antibody binding determinants on the capsid surface of serotype O foot-and-mouth disease virus. The Journal of general virology. 2014; 95(Pt 5):1104–16. https://doi.org/10.1099/vir.0.060939-0 PMID: 24584474.

43. Brocchi EC A.; De Dimone F.; Panina G. F. Characterisation of foot-and-mouth disease virus antibodies. Atti della Societa Italiana delle Scienze Veterinarie. 1983; 36:576–8.

44. Adams JJ, Sidhu SS. Synthetic antibody technologies. Curr Opin Struct Biol. 2014; 24:1–9. https://doi.org/10.1016/j.sbi.2013.11.003 PMID: 24721448.

45. Riechmann L, Clark M, Waldmann H, Winter G. Shaping human antibodies for therapy. Nature. 1988; 332(6263):323–7. https://doi.org/10.1038/332323a0 PMID: 3127726.

46. Boulianne GL, Hozumi N, Shulman MJ. Production of functional chimaeric mouse/human antibody. Nature. 1984; 312(5995):643–6. PMID: 6095115.

47. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proceedings of the National Academy of the United States of America. 1984; 81(21):6851–5. PMID: 6436822.

48. Neuberger MS, Williams GT, Mitchell EB, Jouhal SS, Flanagan JR, Rabbits TH. A hapten-specific chimeric IgE antibody with human physiological effector function. Nature. 1985; 314(6008):269–70. PMID: 2580239.

49. De Castro MP. Behaviour of the foot-and-mouth disease virus in cell cultures: susceptibility of the IBRS-2 cell line. Arch Inst Biol Sao Paulo. 1964; 31:63–78.

50. Clackson T, Hoogenboom HR, Griffiths AD, Winter G. Making antibody fragments using phage display libraries. Nature. 1991; 352(6363):624–8. https://doi.org/10.1038/352624a0 PMID: 1907718.

51. Orlandi R, Gussow DH, Jones PT, Winter G. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proceedings of the National Academy of Sciences of the United States of America. 1989; 86(10):3833–7. PMID: 2726754.

52. Hoogenboom HR, Griffiths AD, Johnson KS, Chiswell DJ, Hudson P, Winter G. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic acids research. 1991; 19(15):4133–7. PMID: 1908075.
74. Al-Lazikani B, Lesk AM, Chothia C. Standard conformations for the canonical structures of immunoglobulins. Journal of molecular biology. 1997; 273(4):927–48. https://doi.org/10.1006/jmbi.1997.1354 PMID: 9367782.

75. Chothia C, Lesk AM. Canonical structures for the hypervariable regions of immunoglobulins. Journal of molecular biology. 1987; 196(4):901–17. PMID: 3681981.

76. Chothia C, Lesk AM, Gherardi E, Tomlinson IM, Walter G, Marks JD, et al. Structural repertoire of the human VH segments. Journal of molecular biology. 1992; 227(3):799–817. PMID: 1404389.

77. Chothia C, Lesk AM, Levitt M, Amit AG, Mariuzza RA, Phillips SE, et al. The predicted structure of immunoglobulin D1.3 and its comparison with the crystal structure. Science. 1986; 233(4765):755–8. PMID: 3090684.

78. Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, et al. Conformations of immunoglobulin hypervariable regions. Nature. 1989; 342(6252):877–83. https://doi.org/10.1038/342877a0 PMID: 2687698.

79. Martin AC, Thornton JM. Structural families in loops of homologous proteins: automatic classification, modelling and application to antibodies. Journal of molecular biology. 1996; 263(5):800–15. https://doi.org/10.1006/jmbi.1996.0617 PMID: 8947577.

80. Tomlinson IM, Cox JP, Gherardi E, Lesk AM, Chothia C. The structural repertoire of the human V kappa domain. The EMBO journal. 1995; 14(18):4628–38. PMID: 7556106.

81. Tramontano A, Chothia C, Lesk AM. Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins. Journal of molecular biology. 1990; 215(1):175–82. https://doi.org/10.1016/S0022-2836(05)80102-0 PMID: 2118959.

82. Wu S, Cygler M. Conformation of complementarity determining region L1 loop in murine IgG lambda light chain extends the repertoire of canonical forms. Journal of molecular biology. 1993; 229(3):597–601. https://doi.org/10.1006/jmbi.1993.1065 PMID: 8433361.

83. Collis AV, Brouwer AP, Martin AC. Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. Journal of molecular biology. 2003; 325(2):337–54. PMID: 12488099.

84. MacCallum RM, Martin AC, Thornton JM. Antibody-antigen interactions: contact analysis and binding site topography. Journal of molecular biology. 1996; 262(5):732–45. https://doi.org/10.1006/jmbi.1996.0548 PMID: 8876650.

85. Verdaguer N, Mateu MG, Andreu D, Giralt E, Domingo E, Fita I. Structure of the major antigenic loop of foot-and-mouth disease virus complexed with a neutralizing antibody: direct involvement of the Arg-Gly-Asp motif in the interaction. The EMBO journal. 1995; 14(8):1690–6. PMID: 7537661.

86. Dunbar J, Krawczyk K, Leem J, Marks C, Nowak J, Regep C, et al. SAbPred: a structure-based antibody prediction server. Nucleic acids research. 2016; 44(W1):W474–8. Epub 2016/05/01. https://doi.org/10.1093/nar/gkw361 PMID: 27131379.

87. Sturt DI, Levine M, Muirhead H, Stammers DK. Crystal structure of cat muscle pyruvate kinase at a resolution of 2.6 A. Journal of molecular biology. 1979; 134(1):109–42. PMID: 197910/15. PMID: 537059.

88. Hewat EA, Verdaguer N, Fita I, Blakemore W, Brookes S, King A, et al. Structure of the complex of an Fab fragment of a neutralizing antibody with foot-and-mouth disease virus particles: positioning of a highly mobile antigenic loop. The EMBO journal. 1997; 16(7):1492–500. Epub 1997/04/01. https://doi.org/10.1093/emboj/6.7.1492 PMID: 9130694.

89. McCullough KC, Crowther JR, Carpenter WC, Brocchi E, Capucci L, De Simone F, et al. Epitopes on foot-and-mouth disease virus particles. I. Topology. Virology. 1987; 157(2):516–25. PMID: 2435060.

90. Berryman S, Clark S, Monaghan P, Jackson T. Early events in integrin alphavbeta6-mediated cell entry of foot-and-mouth disease virus. Journal of virology. 2005; 79(13):8519–34. https://doi.org/10.1128/JVI.79.13.8519-8534.2005 PMID: 15956594.

91. Shimmon G, Wood BA, Morris A, Miolet V, Graziosi S, Brocchi E, et al. Truncated Bovine Integrin Alpha-v/Beta-6 as a Universal Capture Ligand for FMD Diagnosis. PloS one. 2016; 11(8):e0160696. https://doi.org/10.1371/journal.pone.0160696 PMID: 27494135.

92. Burman A, Clark S, Abrescia NG, Fry EE, Sturt DI, Jackson T. Specificity of the VP1 GH loop of Foot-and-Mouth Disease virus for alphav integrins. Journal of virology. 2006; 80(19):9798–810. https://doi.org/10.1128/JVI.00577-06 PMID: 16973584.

93. Dicara D, Burman A, Clark S, Berryman S, Howard MJ, Hart IR, et al. Foot-and-mouth disease virus forms a highly stable, EDTA-resistant complex with its principal receptor, integrin alphavbeta6: implications for infectiousness. Journal of virology. 2008; 82(3):1537–46. https://doi.org/10.1128/JVI.01480-07 PMID: 1804932.
94. Jackson T, Clark S, Berryman S, Burman A, Cambier S, Mu D, et al. Integrin alphavbeta8 functions as a receptor for foot-and-mouth disease virus: role of the beta-chain cytodomain in integrin-mediated infection. Journal of virology. 2004; 78(9):4533–40. https://doi.org/10.1128/JVI.78.9.4533-4540.2004 PMID: 15078934.

95. Neff S, Sa-Carvalho D, Rieder E, Mason PW, Blystone SD, Brown EJ, et al. Foot-and-mouth disease virus virulent for cattle utilizes the integrin alpha(v)beta3 as its receptor. Journal of virology. 1998; 72(5):3587–94. PMID: 9557639.